Zemplar (paricalcitol)

Override(s)  | Approval Duration
-------------|-------------------
Prior Authorization  | 1 year

Medications
- Zemplar (paricalcitol) oral capsules
- Zemplar (paricalcitol) intravenous solution

APPROVAL CRITERIA

Requests for oral Zemplar (paricalcitol) may be approved when the following criteria are met:

I. Individual is 10 years of age or older; AND
II. Individual is using for prevention or treatment of secondary hyperparathyroidism associated with one of the following diagnoses:
   A. Stage 3 or 4 chronic kidney disease not yet requiring dialysis (pre-dialysis);
   OR
   B. Stage 5 chronic kidney disease requiring dialysis; AND
   C. Individual has a baseline corrected serum calcium level of less than or equal to 9.5 mg/dL; AND
   D. Individual has a serum intact parathyroid hormone (iPTH) level greater than 150 pg/mL.

Requests for Zemplar (paricalcitol) injection may be approved when the following criteria are met:

I. Individual is 5 years of age or older; AND
II. Individual is using to prevent or treat secondary hyperparathyroidism; AND
III. Individual has a diagnosis of Stage 5 chronic kidney disease requiring dialysis; AND
IV. Individual has a serum iPTH level greater than 150 pg/mL.

Zemplar (paricalcitol) agents may not be approved for the following:

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.
CRX-ALL-0381-19
I. Individual has hypercalcemia, defined as a serum corrected total calcium level of greater than 10.2 mg/dL or as determined by the reference laboratory assay (NKF 2003, 2010); OR

II. Using in conjunction with prescription-based doses of vitamin D or its derivatives or current evidence of vitamin D toxicity.

State Specific Mandates

<table>
<thead>
<tr>
<th>State name</th>
<th>Date effective</th>
<th>Mandate details (including specific bill if applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Key References:


DrugPoints® System (electronic version). Truven Health Analytics, Greenwood Village, CO. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2016; Updated periodically.